drugset / Trial / NCT00095251

MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status

NCT00095251

Phase 2 Completed 100 enrolled Vanderbilt University
RandomizedParallel-groupTriple-blindPrevention

Summary

Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).

Timeline

Start
2004-08
Primary completion
2007-08
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.15 ug/kg
Comparator Dexmedetomidine Other / unclassified 0.45 ug/kg
Comparator Lorazepam Small molecule 1 mg
Comparator Lorazepam Small molecule 3 mg

Indications